US FDA Novel Approvals Grew To 60 In 2021; CDER Cleared 50 New Agents, Turned Down 18

Approval total is one of FDA’s highest, but the large number of complete response letters obscures the staggering total of almost 80 new molecular entities and novel biologics that the agency acted on over the year.

FDA Raising The Bar
CDER’S APPROVAL LIFT IN 2021 WAS EVEN MORE WEIGHTED TOWARD PRIORITY REVIEWS THAN USUAL. • Source: Alamy

Despite unprecedented events in public health and politics, the US Food and Drug Administration’s 2021 story about novel agent approvals hit some familiar (but nonetheless impressive) notes: another year of novel drug approval counts that would have been unfathomable in the first decade of the 2000s.

The FDA’s drug and biologics centers approved a combined total of 60 novel agents, just the second time the combined...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>